Replimune Group, Inc. (REPL) — Stock Score Summary

Replimune Group, Inc. (REPL) has a MoatMap StockRank of 15/100 based on Quality (28/100), Value (35/100), and Momentum (37/100) factor scores. The current signal is STRONG SELL. Replimune is a clinical-stage biotechnology company that lacks the proven high ROIC, pricing power, and structural moat required by our Terry Smith lens, while showing no clear alignment with our active macro themes.

Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its lead product candidates are designed to selectively replicate in cancer cells and express immune-stimulating proteins, enhancing the body's anti-tumor response. The company's innovative oncolytic virus platform holds potential to address a broad range of solid tumors, positioning it in a highly specialized and rapidly evolving segment of the oncology market.

Key Financial Metrics

Price$9.24
Market Cap$386M
P/E (Forward)-4.78
Price/Book3.73
Return on Equity-90.9%
Return on Invested Capital-48.9%
Debt/Equity36.26
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-173M

Replimune Group, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Replimune Group, Inc.’s (REPL) StockRank?
MoatMap’s StockRank for Replimune Group, Inc. (REPL) is 15/100, with a Strong Sell signal. It is a composite of Quality (28), Value (35), and Momentum (37) factor ranks across MoatMap’s 19,000+ stock universe.
Does Replimune Group, Inc. have an economic moat?
Replimune Group, Inc. (REPL) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Replimune Group, Inc. a buy, hold, or sell?
MoatMap’s current signal for Replimune Group, Inc. (REPL) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Replimune Group, Inc. in?
Replimune Group, Inc. (REPL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksREPL deep dive reportAI ChampionsHow we score stocksSense-check another stock